Thames Valley Chamber of Commerce logo

Marketing authorisation granted for advanced gene-silencing drug

October 10, 2018

Marketing authorisation granted for advanced gene-silencing drug

Alnylam Pharmaceuticals has announced that marketing authorisation has been granted by the European Commission for the pioneering drug patisiran, which follows approval from the US Food and Drugs Administration in August 2018. Devised for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with Stage 1 or 2 polyneuropathy, the drug is the first-ever RNA interference (RNAi) therapeutic to be approved for use in the UK.

Additionally, it is the first treatment of its type in the world to be approved for use in patients with hATTR amyloidosis, a rare disease that causes amyloid protein to accumulate and damage body organs and tissue. Affecting limb movement, swallowing and vision, and triggering chronic neuropathic pain, the disease is hereditary, progressive and life-threatening.

The cutting-edge drug, branded as Onpattro, modifies the course of the disease by employing the Nobel Prize-winning principle of RNA interference to target the faulty protein that is causing it. Marketing authorisation for patisiran was based on positive results from a double-blind, global, placebo-controlled study of 225 hATTR amyloidosis patients with polyneuropathy. Published in the New England Journal of Medicine, a report on the research said disease progression was “haltered or reversed” in patients who received the active drug.

With final guidance expected to be issued in 2019, the National Institute for Health and Care Excellence (NICE), which approves new NHS treatments, is now reviewing the drug.

“Today marks a welcome step forward in the treatment of hATTR amyloidosis in the UK, as well as Alnylam’s journey to create a new wave of innovative, first-in-class RNAi therapeutics. We have real potential to help maintain quality of life for people affected by this ghastly condition. Our focus now will be on working closely with all the relevant health authorities so that all eligible patients across the UK have the option to access this important medicine as soon as possible.”

Brendan Martin, UK & Ireland General Manager – Alnylam Pharmaceuticals

Read more here.

Headquartered in Cambridge, MA, Alnylam is one of the most promising US biotechnology companies. Leading the translation of RNA interference into a new class of innovative medicines to transform the lives of those with rare diseases, it opened its European Drug Development and Commercial Headquarters in Maidenhead, Thames Valley in September 2016.


← back to Blog

About the author

Katherine Chapanionek

Katherine Chapanionek

We work alongside the Department for International Trade (DIT), the region’s Local Enterprise Partnerships (LEPs), Local Authorities and professional service providers to support foreign direct investment (FDI) into the Thames Valley. Outside of London, the Thames Valley is consistently the highest performing region in attracting foreign-direct investment into the United Kingdom.

Add your comment

Sign in or sign up to leave a comment.


Share this content
Global Brands
Find out which Global Brands call the Thames Valley home
Lifestyle & Environment
Explore the Lifestyle & Environment of the region

The Chamber of Commerce

Paul Britton
Chief Executive

We work alongside the Department for International Trade (DIT), the region’s Local Enterprise Partnerships (LEPs), Local Authorities and professional service providers to support foreign direct investment (FDI) into the Thames Valley.

For the 2017/18 financial year, we are proud to report that the Thames Valley has retained its status as the number one region in the UK, outside of London, for attracting FDI. 191 FDI projects were recorded as entering the region, with a high proportion of these investors strongly supported by the Chamber.

Contact Paul Britton

New Blog articles

Oxfordshire-based Reaction Engines has been given the green light to begin a testing programme for the core section of SABRE, its proposed single-stage-to-orbit spaceplane engine.

Keep reading →

As part of the Government’s modern Industrial Strategy, Business Secretary Greg Clark and Digital Secretary Jeremy Wright have announced a nationwide government-industry package to support

Keep reading →

This website is managed by:

Thames Valley Chamber of Commerce Group

The Thames Valley Chamber is a proven centre of excellence for International Trade and Inward Investment support services. Our team provides practical support to help inbound and established businesses reach their potential. We are one of the largest Chambers accredited by the British Chambers of Commerce in the UK and the only accredited Chamber in the region.